Financials in USD. Standardized financial statements.
A compact view of how CBD Life Sciences Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $98,321 | $108,891 | $167,147 | $160,241 | $59,257 | $225,897 | $79,635 | $122,789 | $155,553 | $0 |
| Revenue Growth? | -9.7% | -34.9% | +4.3% | +170.4% | -73.8% | +183.7% | -35.1% | -21.1% | 0.0% | 0.0% |
| Cost of Revenue? | $56,833 | $118,781 | $197,749 | $440,501 | $207,506 | $438,127 | $43,000 | $0 | $0 | $0 |
| Gross Profit? | $41,488 | -$9,890 | -$30,602 | -$280,260 | -$148,249 | -$212,230 | $36,633 | $122,789 | $155,553 | $0 |
| Gross Margin? | +42.2% | -9.1% | -18.3% | -174.9% | -250.2% | -93.9% | +46.0% | +100.0% | +100.0% | 0.0% |
| Operating Expenses? | $143,190 | $747,299 | $47,974 | $579,545 | $4.98M | $171,862 | $906,253 | $883,803 | $499,044 | $155,724 |
| Operating Income? | -$101,702 | -$757,189 | -$78,574 | -$859,800 | -$5.13M | -$384,090 | -$869,620 | -$780,139 | -$367,135 | -$156,334 |
| EBITDA? | -$101,702 | -$701,632 | -$23,017 | -$806,248 | -$4.89M | -$1.31M | -$869,620 | -$741,558 | -$304,968 | -$60,361 |
| Income Before Tax | -$48,929 | -$757,189 | -$78,574 | -$859,804 | -$5.13M | -$1.69M | -$861,010 | -$780,139 | -$367,135 | -$156,334 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $15,267 | $23,503 | $610 |
| Net Income? | -$48,929 | -$757,189 | -$78,574 | -$859,804 | -$5.13M | -$1.69M | -$861,010 | -$780,139 | -$367,135 | -$156,334 |
| EPS? | $0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 | $-428.18 | $-2294.59 | $-2405.14 |
| Diluted EPS? | $0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 | $-428.18 | $-2294.59 | $-2405.14 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality